Screener
Ligand Pharmaceuticals LGND Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Ligand Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
FAQ
- What is Ligand Pharmaceuticals's debt-to-equity?
- Ligand Pharmaceuticals (LGND) reported debt-to-equity of 1.2× in Q2 2026.
- How has Ligand Pharmaceuticals's debt-to-equity changed year-over-year?
- Ligand Pharmaceuticals's debt-to-equity increased by 16847.8% year-over-year, from 0× to 1.2×.
- What is the long-term trend for Ligand Pharmaceuticals's debt-to-equity?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's debt-to-equity has grown at a -29.0% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Ligand Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude